News articles about Leap Therapeutics (NASDAQ:LPTX) have been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Leap Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.3356440908323 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

Separately, Zacks Investment Research raised Leap Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 6th.

Shares of Leap Therapeutics (NASDAQ LPTX) traded down 3.23% during trading on Wednesday, reaching $5.99. The company had a trading volume of 56,027 shares. The company has a 50 day moving average of $6.18 and a 200-day moving average of $7.19. The firm’s market capitalization is $56.28 million. Leap Therapeutics has a 52-week low of $5.85 and a 52-week high of $10.10.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Friday, August 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). Equities analysts expect that Leap Therapeutics will post ($3.16) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Insider Buying and Selling by Quarter for Leap Therapeutics (NASDAQ:LPTX)

Receive News & Stock Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related stocks with our FREE daily email newsletter.